Novo Nordisk's buyback reaches DKK 9.0 billion of a DKK 15 billion program

Novo Nordisk disclosed on September 7, 2026, that it has repurchased 32,034,179 B shares since February 4, 2026, at an average price of DKK 281.63 per share, for a total of DKK 9,021,774,283 ^[1][2]. That is about 60% of the way through a share buyback program the company says can reach up to DKK 15 billion over a 12-month period that began February 4, 2026 ^[1][2].

The buyback is being carried out in stages. A sub-program that started May 6, 2026 allows purchases of up to DKK 11,200,000,010.45 through February 1, 2027 ^[1][2]. Under that piece alone, Novo Nordisk has bought 17,275,000 shares for DKK 5,221,774,293 ^[1][2]. In the most recent days reported, from August 31 through September 4, 2026, the company bought between 200,000 and 215,000 shares per day, at prices ranging from DKK 291.92 to DKK 305.35 ^[1][2]. Those daily prices are above the overall average of DKK 281.63, meaning the stock has been trading higher in early September than it did earlier in the buyback period ^[1][2].

As a result of these purchases, Novo Nordisk now holds 46,074,876 B shares as treasury shares, which is 1.0% of its total share capital of 4,465,000,000 A and B shares ^[1][2]. The company's B shares trade on Nasdaq Copenhagen under the ticker Novo-B, and its American Depositary Receipts trade on the New York Stock Exchange under the ticker NVO ^[1][2]. Novo Nordisk reports employing about 68,800 people across 80 countries and selling products in around 170 countries ^[1].

A share buyback is when a company uses its own cash to purchase shares of its own stock on the open market. Companies do this for several reasons, including returning cash to shareholders, reducing the number of shares outstanding, or signaling that management believes the stock is undervalued. The filings describing this program do not state Novo Nordisk's specific reasons for the buyback, nor do they address the company's product pipeline, drug pricing, or supply of GLP-1 medications like Ozempic, Wegovy, or Rybelsus ^[1][2].

Why it matters for patients

This buyback is a corporate finance action, not a change to any Novo Nordisk medication, price, insurance coverage, or availability. Patients taking or considering semaglutide products will not see a direct effect on their prescriptions, out-of-pocket costs, or pharmacy access from this announcement, based on what the filings describe ^[1][2].

Where this can matter indirectly is for people who hold Novo Nordisk stock, including through retirement accounts, mutual funds, or employer plans, since buybacks can affect share price and the number of shares outstanding ^[1][2]. It can also matter as one data point in how investors and analysts read the company's financial confidence, though the sources here do not include any statement from Novo Nordisk explaining its rationale or connecting the buyback to drug development, competition, or sales trends. Anyone trying to understand what this means for the company's future medicines or pricing would need additional information not contained in these filings.

What happens next

The overall DKK 15 billion program is set to run through the 12-month period beginning February 4, 2026, meaning it is expected to continue into early 2027 ^[1][2]. The sub-program that started May 6, 2026, has an outer limit date of February 1, 2027 ^[1][2]. Novo Nordisk has been issuing regular updates on repurchase activity, and further announcements are likely as the program progresses, though no additional dates or details beyond September 4, 2026 are included in these filings ^[1][2].